Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Status:
Recruiting
Trial end date:
2021-03-22
Target enrollment:
Participant gender:
Summary
To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of
oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC)
refractory to transarterial chemoembolization(TACE)
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University Guangzhou No.12 People's Hospital Kaiping Central Hospital